Abstract:Molecularly targeted therapies are at the forefront of clinical science, and are expected to lead to personalization of medical treatments for each patient. Most such therapies are directed at inhibiting specific signal transduction enzymes or pathways, thus creating a critical need for assays capable of measuring the activities of these proteins in disease models and in patient samples. The ability to measure relevant enzyme activity in primary cell samples at baseline and/or after treatment would provide the ability to tailor patient therapy based on aberrant signal transduction, validate mechanisms of resistance in patients, and would offer an invaluable pharmacodynamic tool to assess whether resistance is associated with inadequate target inhibition. Here we report our current efforts to create the analytical and chemical tools needed to directly measure the enzymatic activities of therapeutic targets including protein kinases, lipid modifying enzymes and the proteasome. Fluorescent reagents are under development that report the activity of these various enzymes in model cells lines and primary cells. The basic design incorporates enzyme substrates that are modified to create compounds which can be loaded into cells where they are modified by the enzyme of interest. Work has included modification of peptides to confer membrane permeability and to achieve long intracellular lifetimes. Microelectrophoretic separations combined with low-level fluorescence detection enable the quantitative analysis of these compounds from single mammalian cells. This capability addresses three major issues currently faced in the biochemical analysis of clinical samples: the need for direct measurement of the enzymatic activity of target proteins; sample size requirements that are feasible for clinical implementation; and sample heterogeneity that can mask pertinent aspects related to therapeutic response.

Biophysical Assays for Investigating Modulators of Macromolecular Complexes: An Overview

Methods to Profile the Macromolecular Targets of Small Compounds.

Recent advances and method development for drug target identification

Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition

Investigating Targets for Neuropharmacological Intervention by Molecular Dynamics Simulations

Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures

Biophysical Methods for Attomolar Detection of Compounds Acting on Protein Oligomer States

Trends using biological target-based assays for drug detection in complex sample matrices

Single-Cell Biochemical Assays For The Molecular Targets Of Disease

Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview

Discovery of GPCR ligands for probing signal transduction pathways

Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands

Tackling assay interference associated with small molecules

Biomembrane models and drug-biomembrane interaction studies: Involvement in drug design and development

Proteomic methods for drug target discovery

Drugging Membrane Protein Interactions

Molecular Docking and Structure-Based Drug Design Strategies

Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

Exploiting Cell-Based Assays to Accelerate Drug Development for G Protein-Coupled Receptors

Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays

Online Scheduling of Multiprocessor Jobs with Idle Regulation